Hyderabad-based VINS Bioproducts gets DCGI nod to start clinical trials for VINCOV-19
VINS Bioproducts said that VINCOV-19, developed by VINS Bioproducts in collaboration with CCMB and the University of Hyderabad (UoH), as an antidote and a cure, is a significant step in the fight against coronavirus.
By ANI| Updated: 26th April 2021 4:34 pm IST Representative Image
Hyderabad: VINS Bioproducts on Monday received approval from the Drugs Controller General of India (DCGI) to commence the clinical trials for VINCOV-19, an antidote, and a cure against COVID-19, the Hyderabad based immunological company said.
In a statement, VINS Bioproducts said that VINCOV-19, developed by VINS Bioproducts in collaboration with Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), as an antidote and a cure, is a significant step in the fight against coronavirus.
VINS Bioproducts gets DCGI nod to commence clinical trials for VINCOV-19 ANI | Updated: Apr 26, 2021 14:59 IST
Hyderabad (Telangana) [India], April 26 (ANI): VINS Bioproducts on Monday received approval from the Drugs Controller General of India (DCGI) to commence the clinical trials for VINCOV-19, an antidote, and a cure against COVID-19, the Hyderabad based immunological company said.
In a statement, VINS Bioproducts said that VINCOV-19, developed by VINS Bioproducts in collaboration with Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), as an antidote and a cure, is a significant step in the fight against coronavirus.
The clinical trials of VINCOV-19 will involve over 300 subjects spread across the country. The safety and efficacy of the antibodies will be examined in a group of around 300 patients, with COVID-19, informed the statement.